WebOct 9, 2024 · NEW YORK (GenomeWeb) – Biotechnology company GenAhead Bio said today that it has signed a non-exclusive license agreement with ERS Genomics that provides GenAhead with access to ERS' CRISPR-Cas9 genome editing intellectual property. Fujisawa, Japan-based GenAhead, which was spun out of Takeda … WebJun 20, 2024 · A research publication 「ERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes」 project from T-CiRA Joint Program led by Associate Professor Yoshinori Yoshida was published in Nature Communications on June 21th, 2024.
Improve Gene-Editing Success with CRISPR-SNIPER Technology
WebSep 2, 2024 · CRISPR-SNIPER combines the stem cell expertise of REPROCELL with the genome editing knowledge of GenAhead Bio to provide clinically relevant disease models. Although there are many companies that offer gene editing and iPSC technologies, there are few that combine both services with a high success rate. WebOct 9, 2024 · This service is offered in collaboration with GenAhead Bio Inc. (Kanagawa, Japan; hereinafter referred to as “GenAhead”). GenAhead is a venture company established by a team of experts in genetic modification technology. Since April 2024, REPROCELL has had a strategic investment in GenAhead. trepanning companies
Japan Biotech Startups Directory 2024: Establishment, Technology ...
WebOct 5, 2024 · Researchers at GenAhead Bio have created a more sensitive CRISPR screening using droplet digital PCR (ddPCR) in order to improve the success rate of challenging genome editing projects. In this article, … WebGENAHEAD BIO, INC. Company Profile FUJISAWA, KANAGAWA, Japan Competitors, Financials & Contacts - Dun & Bradstreet Find company research, competitor … WebApr 13, 2024 · CRISPR-Cas9 has emerged as a powerful technology for generating disease-specific models, allowing the discrimination between the effects of causative disease-causing mutation and genetic background of the cells, which would have been otherwise impossible when using human induced pluripotent stem cells (iPSCs) alone. tenant by entity